[HCV entry as a new therapeutic target in chronic hepatitis C].
According to WHO data the hepatitis C virus (HCV) has already infected 170 million people worldwide, and 750,000 of them in Poland what amounts some 1.4% of general country population. Currently used antiviral therapy with pegylated interferon alpha and ribavirin has only 50% effectiveness. Many new drugs and molecules, especially inhibiting viral replication, are studied in preclinical and clinical trials. However, still unknown HCV entry process can be a new, promising therapeutic target in chronic HCV infection.
Dabrowska
Magdalena M
MM
Medical University of Białystok, Department of Infectious Diseases and Hepathology, Poland. m.dabrowska@op.pl
Panasiuk
Anatol
A
Flisiak
Robert
R
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D016174:Hepacivirus / Q000472:pathogenicity; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D053585:Virus Attachment / Q000187:drug effects*; D053586:Virus Internalization / Q000187:drug effects*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a